{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:02:28Z","timestamp":1779264148464,"version":"3.51.4"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-162 118"],"award-info":[{"award-number":["PJT-162 118"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-183 583"],"award-info":[{"award-number":["PJT-183 583"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W-1253"],"award-info":[{"award-number":["W-1253"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000222","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-22\\u201332 059"],"award-info":[{"award-number":["G-22\\u201332 059"]}],"id":[{"id":"10.13039\/501100000222","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.phrs.2023.106843","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T21:17:51Z","timestamp":1688419071000},"page":"106843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor"],"prefix":"10.1016","volume":"194","author":[{"given":"Marlys L.","family":"Koschinsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik S.G.","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-1120","authenticated-orcid":false,"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106843_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2022.04.017","article-title":"The long journey of lipoprotein(a) from cardiovascular curiosity to therapeutic target","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib2","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/01.ATV.12.10.1214","article-title":"Apo(a) isoforms predict risk for coronary heart disease: a study in six populations","volume":"12","author":"Sandholzer","year":"1992","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.phrs.2023.106843_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a) - resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2023.106843_bib4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCRESAHA.118.313864","article-title":"Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis","volume":"124","author":"Tsimikas","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2023.106843_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2023.106843_bib7","doi-asserted-by":"crossref","first-page":"11992","DOI":"10.1073\/pnas.94.22.11992","article-title":"Convergent evolution of apolipoprotein(a) in primates and hedgehog","volume":"94","author":"Lawn","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.phrs.2023.106843_bib8","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1016\/S0021-9258(18)83643-2","article-title":"Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis","volume":"264","author":"Tomlinson","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib9","doi-asserted-by":"crossref","first-page":"15777","DOI":"10.1021\/bi00048a023","article-title":"Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a)","volume":"34","author":"Gabel","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106843_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"Van der Hoek","year":"1993","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.phrs.2023.106843_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/hmg\/2.7.933","article-title":"Molecular definition of the extreme size polymorphism in apolipoprotein(a)","volume":"2","author":"Lackner","year":"1993","journal-title":"Hum. Mol. Genet"},{"key":"10.1016\/j.phrs.2023.106843_bib12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00220066","article-title":"The apolipoprotein(a) gene: a transcribed hypervariable locus controlling plasma lipoprotein(a) concentration","volume":"90","author":"Kraft","year":"1992","journal-title":"Hum. Genet"},{"key":"10.1016\/j.phrs.2023.106843_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1021\/bi010964i","article-title":"Comparative analyses of the lysine binding site properties of apolipoprotein(a) Kringle IV Types 7 and 10","volume":"41","author":"Rahman","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106843_bib14","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1074\/jbc.270.11.6227","article-title":"Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a)","volume":"270","author":"Ernst","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib15","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1161\/01.ATV.16.12.1559","article-title":"Lipoprotein(a) assembly - Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation","volume":"16","author":"Gabel","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib16","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1073\/pnas.86.10.3847","article-title":"Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin","volume":"86","author":"Harpel","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.phrs.2023.106843_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2023.106843_bib18","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib19","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib21","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a european atherosclerosis society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib23","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib24","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic factors explain a major fraction of the 50% lower lipoprotein[a] concentrations in Finns","volume":"38","author":"Erhart","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib26","first-page":"829","article-title":"Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes","volume":"51","author":"Austin","year":"1992","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.phrs.2023.106843_bib27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0021-9150(91)90191-5","article-title":"The NHLBI Twin Study: heritability of apolipoprotein A-I and B, and low density lipoprotein subclasses and concordance for lipoprotein(a)","volume":"91","author":"Lamon-Fava","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1126\/science.2530631","article-title":"The mysteries of lipoprotein(a)","volume":"246","author":"Utermann","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.106843_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib30","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI115248","article-title":"Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis","volume":"87","author":"Lackner","year":"1991","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib31","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1016\/S0021-9258(17)37076-X","article-title":"Molecular basis for null lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon","volume":"269","author":"White","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib32","doi-asserted-by":"crossref","first-page":"32403","DOI":"10.1074\/jbc.271.50.32403","article-title":"The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells","volume":"271","author":"Brunner","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib33","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1172\/JCI116370","article-title":"Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels","volume":"91","author":"Cohen","year":"1993","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI117126","article-title":"Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles","volume":"93","author":"Perombelon","year":"1994","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib35","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib38","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/ATVBAHA.120.315300","article-title":"Genome-wide association study and identification of a protective missense variant on lipoprotein(a) concentration: protective missense variant on lipoprotein(a) concentration-brief report","volume":"41","author":"Said","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.atherosclerosis.2022.06.1023","article-title":"Sex differences of lipoprotein(a) levels and associated risk of morbidity and mortality by age: The Copenhagen General Population Study","volume":"355","author":"Simony","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.maturitas.2022.09.012","article-title":"The effect of menopause on lipoprotein (a) concentrations: A systematic review and meta-analysis","volume":"167","author":"Anagnostis","year":"2023","journal-title":"Maturitas"},{"key":"10.1016\/j.phrs.2023.106843_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.phrs.2023.106843_bib43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib45","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib47","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/CIRCULATIONAHA.122.061451","article-title":"Multiancestry genome-wide association study of aortic stenosis identifies multiple novel loci in the Million Veteran program","volume":"147","author":"Small","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib48","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/eurheartj\/ehad055","article-title":"Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein","volume":"44","author":"Thomas","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105812","article-title":"Lipoprotein(a): knowns, unknowns and uncertainties","volume":"173","author":"Ruscica","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2023.106843_bib50","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/eurjpc\/zwaa063","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","volume":"28","author":"Welsh","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib51","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0021-9150(81)90103-9","article-title":"Lipoprotein Lp(a) and the risk for myocardial infarction","volume":"38","author":"Kostner","year":"1981","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib54","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/eurjpc\/zwac271","article-title":"Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults","volume":"30","author":"Kim","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","article-title":"Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees","volume":"33","author":"Kronenberg","year":"2022","journal-title":"Curr. Opin. Lipido"},{"key":"10.1016\/j.phrs.2023.106843_bib57","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib58","first-page":"140","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019"},{"key":"10.1016\/j.phrs.2023.106843_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.atherosclerosis.2023.01.014","article-title":"Trends and consequences of lipoprotein(a) testing: Cross-sectional and longitudinal health insurance claims database analyses","volume":"367","author":"Sturzebecher","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.atherosclerosis.2023.02.007","article-title":"Clinics Network, Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network","volume":"370","author":"Catapano","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"key":"10.1016\/j.phrs.2023.106843_bib62","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib63","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein(a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib64","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.atherosclerosis.2019.08.019","article-title":"The challenges of measuring Lp(a): a fight against Hydra?","volume":"289","author":"Kronenberg","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib66","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","article-title":"Towards an SI-traceable reference measurement system for seven serum apolipoproteins using bottom-up quantitative proteomics: conceptual approach enabled by cross-disciplinary\/cross-sector collaboration","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib67","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/clinchem\/hvac203","article-title":"Commutability assessment of candidate reference materials for lipoprotein(a) by comparison of a ms-based candidate reference measurement procedure with immunoassays","volume":"69","author":"Dikaios","year":"2023","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib69","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/clinchem\/hvac204","article-title":"Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests","volume":"69","author":"Ruhaak","year":"2023","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib70","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1503\/cmaj\/051291","article-title":"Troponin: the biomarker of choice for the detection of cardiac injury","volume":"173","author":"Babuin","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.phrs.2023.106843_bib71","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.kint.2016.01.007","article-title":"High-density lipoprotein cholesterol on a roller coaster: where will the ride end?","volume":"89","author":"Kronenberg","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2023.106843_bib72","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2023.106843_bib73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","article-title":"Mendelian Randomization: Principles and its usage in Lp(a) research","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib74","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","article-title":"Apolipoprotein(a) Kringle IV repeat number predicts risk for coronary heart disease","volume":"16","author":"Kraft","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib75","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.106843_bib76","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the finnish founder population","author":"Lim","year":"2014","journal-title":"PLoS. Genet 10"},{"key":"10.1016\/j.phrs.2023.106843_bib78","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib79","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/01.ATV.14.11.1792","article-title":"Binding of recombinant apolipoprotein(a) to extracellular matrix proteins","volume":"14","author":"Van der Hoek","year":"1994","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.phrs.2023.106843_bib80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(99)00064-7","article-title":"Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux","volume":"143","author":"Nielsen","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib81","doi-asserted-by":"crossref","first-page":"13681","DOI":"10.1021\/bi00212a037","article-title":"Comparison of the lysine binding functions of lipoprotein(a) and plasminogen","volume":"32","author":"Hooverplow","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106843_bib82","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/bi048156p","article-title":"Baboon lipoprotein(a) binds very weakly to lysine-agarose and fibrin despite the presence of a strong lysine-binding site in apolipoprotein(a) kringle IV type 10","volume":"44","author":"Belczewski","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106843_bib83","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI119671","article-title":"Lipoprotein(a) vascular accumulation in mice - In vivo analysis of the role of lysine binding sites using recombinant adenovirus","volume":"100","author":"Hughes","year":"1997","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib84","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1074\/jbc.M309705200","article-title":"The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells","volume":"279","author":"Pellegrino","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib85","doi-asserted-by":"crossref","first-page":"30503","DOI":"10.1074\/jbc.M802648200","article-title":"Apolipoprotein(a), through its strong lysine-binding site in KIV(10'), mediates increased endothelial cell contraction and permeability via a Rho\/Rho kinase\/MYPT1-dependent pathway","volume":"283","author":"Cho","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib86","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1091\/mbc.e12-08-0637","article-title":"Apolipoprotein(a) stimulates nuclear translocation of \u03b2-catenin: a novel pathogenic mechanism for lipoprotein(a)","volume":"24","author":"Cho","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.phrs.2023.106843_bib87","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2023.106843_bib88","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/eurheartj\/ehaa171","article-title":"Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)","volume":"41","author":"Stiekema","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib89","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib90","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.09.010","article-title":"Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress","volume":"12","author":"Seimon","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2023.106843_bib91","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.8503012","article-title":"Proliferation of human smooth muscle cells promoted by lipoprotein(a)","volume":"260","author":"Grainger","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.106843_bib92","doi-asserted-by":"crossref","first-page":"55187","DOI":"10.1074\/jbc.M409860200","article-title":"Koschinsky, Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of TGF-beta activation and on the presence of kringle IV type 9","volume":"279","author":"C.H. O'neil","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib93","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib94","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.jacc.2006.03.001","article-title":"Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck Study","volume":"47","author":"Tsimikas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib95","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1161\/CIRCULATIONAHA.120.052023","article-title":"Long Noncoding RNA MIAT Controls Advanced Atherosclerotic Lesion Formation and Plaque Destabilization","volume":"144","author":"Fasolo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib96","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.atherosclerosis.2022.04.001","article-title":"Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology","volume":"349","author":"Koschinsky","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib97","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib98","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib99","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2022.04.009","article-title":"Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis","volume":"349","author":"Boffa","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib100","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib101","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00015a028","article-title":"Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation","volume":"34","author":"Sangrar","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106843_bib102","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1161\/ATVBAHA.112.248765","article-title":"Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis","volume":"32","author":"Kamstrup","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib103","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib104","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib105","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood.V98.10.2980","article-title":"Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis","volume":"98","author":"Caplice","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2023.106843_bib106","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/01.ATV.18.9.1393","article-title":"Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN","volume":"18","author":"Rand","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11239-021-02515-2","article-title":"Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity","volume":"53","author":"Kille","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.phrs.2023.106843_bib108","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1007\/s12325-020-01483-y","article-title":"Relation of High Lipoprotein (a) Concentrations to Platelet Reactivity in Individuals with and Without Coronary Artery Disease","volume":"37","author":"Salsoso","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2023.106843_bib109","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1373\/clinchem.2017.276931","article-title":"High Lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a mendelian randomization study","volume":"63","author":"Langsted","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib111","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/heartjnl-2021-319804","article-title":"Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis","volume":"108","author":"Kaiser","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.phrs.2023.106843_bib113","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1093\/eurheartj\/ehac377","article-title":"Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification","volume":"43","author":"Kaiser","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib114","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1093\/eurheartj\/ehac436","article-title":"Lipoprotein(a) and aortic valve stenosis: work in progress","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcmg.2022.09.007","article-title":"Lipoprotein(a) and Aortic Valve Calcification: The Multi-Ethnic Study of Atherosclerosis","volume":"16","author":"Bhatia","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.phrs.2023.106843_bib116","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","article-title":"Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization","volume":"63","author":"Mahmut","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib117","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cmet.2011.02.016","article-title":"Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium","volume":"13","author":"Zhou","year":"2011","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2023.106843_bib118","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.115.016757","article-title":"Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve","volume":"132","author":"Bouchareb","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib119","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/joim.12519","article-title":"Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease","volume":"280","author":"Nsaibia","year":"2016","journal-title":"J. Intern Med"},{"key":"10.1016\/j.phrs.2023.106843_bib120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): An underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib121","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1161\/CIRCULATIONAHA.122.063481","article-title":"Toll-like receptor 3 mediates aortic stenosis through a conserved mechanism of calcification","volume":"147","author":"Gollmann-Tepekoylu","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib122","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pathophys.2004.06.007","article-title":"Atherogenesis and vascular calcification in mice expressing the human LPA gene","volume":"11","author":"Teivainen","year":"2004","journal-title":"Pathophysiology"},{"key":"10.1016\/j.phrs.2023.106843_bib123","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1194\/jlr.M006742","article-title":"Lipoprotein(a) accelerates atherosclerosis in uremic mice","volume":"51","author":"Pedersen","year":"2010","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10557-015-6634-1","article-title":"Experimental animal models evaluating the causal role of lipoprotein(a) in atherosclerosis and aortic stenosis","volume":"30","author":"Yeang","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2023.106843_bib125","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1074\/jbc.272.8.5048","article-title":"Influence of allelic variation on apolipoprotein(a) folding in the endoplasmic reticulum","volume":"272","author":"White","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib126","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-2275(20)33367-8","article-title":"Presecretory degradation of apolipoprotein[a] is mediated by the proteasome pathway","volume":"40","author":"White","year":"1999","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib127","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2023.106843_bib128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0005-2760(79)90131-0","article-title":"K. Bolzano, F. Sandhofer, Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B","volume":"575","author":"Krempler","year":"1979","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.phrs.2023.106843_bib129","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","article-title":"Recent advances in demystifying the metabolism of lipoprotein(a)","volume":"349","author":"Chemello","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib131","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1161\/01.ATV.0000188555.60475.c2","article-title":"Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis","volume":"25","author":"Ikewaki","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib132","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/MOL.0000000000000823","article-title":"Understanding the ins and outs of lipoprotein (a) metabolism","volume":"33","author":"Boffa","year":"2022","journal-title":"Curr. Opin. Lipido"},{"key":"10.1016\/j.phrs.2023.106843_bib133","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/ATVBAHA.121.317335","article-title":"Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion","volume":"42","author":"Youssef","year":"2022","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib134","doi-asserted-by":"crossref","first-page":"9919","DOI":"10.1021\/bi060283t","article-title":"Catalysis of Covalent Lp(a) Assembly: Evidence for an Extracellular Enzyme Activity that Enhances Disulfide Bond Formation","volume":"45","author":"Becker","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.106843_bib135","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.1016\/S0021-9258(19)36587-1","article-title":"der Hoek, Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100","volume":"268","author":"Koschinsky","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib136","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","article-title":"Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo","volume":"270","author":"Callow","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib137","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00041433-199504000-00003","article-title":"Biosynthesis and metabolism of lipoprotein(a)","volume":"6","author":"White","year":"1995","journal-title":"Curr. Opin. Lipido"},{"key":"10.1016\/j.phrs.2023.106843_bib138","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib139","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.phrs.2023.106843_bib140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.metabol.2012.07.024","article-title":"Lipoprotein(a) metabolism: potential sites for therapeutic targets","volume":"62","author":"Hoover-Plow","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2023.106843_bib141","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1172\/JCI117794","article-title":"The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans","volume":"95","author":"Rader","year":"1995","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib142","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1194\/jlr.M500249-JLR200","article-title":"Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]","volume":"46","author":"Cain","year":"2005","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib143","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0022-2275(20)37595-7","article-title":"Interaction of a recombinant form of apolipoprotein[a] with human fibroblasts and with the human hepatoma cell line HepG2","volume":"37","author":"Tam","year":"1996","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib144","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1172\/JCI110896","article-title":"Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man","volume":"71","author":"Krempler","year":"1983","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib145","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.106843_bib146","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","article-title":"Effect of Alirocumab on Lipoprotein(a) Over >\/=1.5 Years (from the Phase 3 ODYSSEY Program)","volume":"119","author":"Gaudet","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib147","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2014.01.006","article-title":"Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials","volume":"63","author":"Raal","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib148","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1194\/jlr.P065334","article-title":"PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role","volume":"57","author":"Raal","year":"2016","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib149","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180869","article-title":"Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin\/kexin type 9","volume":"12","author":"Romagnuolo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2023.106843_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2023.106843_bib151","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans","volume":"135","author":"Reyes-Soffer","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib152","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J. Intern. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib153","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib154","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0021-9150(91)90025-X","article-title":"Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects","volume":"87","author":"Knight","year":"1991","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib155","article-title":"Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9","volume":"2023","author":"Roubtsova","year":"1868","journal-title":"Biochim Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.phrs.2023.106843_bib156","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.106843_bib157","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib158","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib159","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehz776","article-title":"Statins and increases in Lp(a): an inconvenient truth that needs attention","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib160","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib161","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"O.-D.T. Investigators, Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib162","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1194\/jlr.M038877","article-title":"Scavenger receptor-BI is a receptor for lipoprotein(a)","volume":"54","author":"Yang","year":"2013","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib163","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCGENETICS.116.001402","article-title":"SCARB1 Gene Variants Are Associated With the Phenotype of Combined High High-Density Lipoprotein Cholesterol and High Lipoprotein (a)","volume":"9","author":"Yang","year":"2016","journal-title":"Circ. Cardiovasc. Genet"},{"key":"10.1016\/j.phrs.2023.106843_bib164","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/CIRCRESAHA.116.310272","article-title":"Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a)","volume":"120","author":"Sharma","year":"2017","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2023.106843_bib165","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1111\/jth.15014","article-title":"Functions of the plasminogen receptor Plg-R(KT)","volume":"18","author":"Miles","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.phrs.2023.106843_bib166","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib167","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib168","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lp(a) (Lipoprotein[a])-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib169","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/164_2021_504","article-title":"Lipoprotein(a)","volume":"270","author":"Kronenberg","year":"2022","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.phrs.2023.106843_bib170","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2023.106843_bib171","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2023.106843_bib172","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib173","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehy862","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","volume":"40","author":"Stiekema","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib174","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2023.106843_bib175","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"O.O. Investigators, Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib176","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib177","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2023.106843_bib178","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jacl.2014.03.006","article-title":"Dramatic lowering of very high Lp(a) in response to niacin","volume":"8","author":"Li","year":"2014","journal-title":"J. Clin. Lipido"},{"key":"10.1016\/j.phrs.2023.106843_bib179","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib180","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib181","article-title":"Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study","volume":"13","author":"D'Erasmo","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.phrs.2023.106843_bib182","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib183","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11883-007-0008-5","article-title":"The role of CETP inhibition in dyslipidemia","volume":"9","author":"El Harchaoui","year":"2007","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.phrs.2023.106843_bib184","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.phrs.2023.106843_bib185","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib186","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2023.106843_bib187","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib188","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib189","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib190","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2023.106843_bib191","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1172\/JCI109813","article-title":"Turnover of lipoprotein(a) in man","volume":"65","author":"Krempler","year":"1980","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib192","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1172\/JCI116221","article-title":"Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production","volume":"91","author":"Rader","year":"1993","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2023.106843_bib193","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2023.106843_bib194","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2020.1757070","article-title":"Gene-based therapy in lipid management: the winding road from promise to practice","volume":"29","author":"Tromp","year":"2020","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.phrs.2023.106843_bib195","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.106843_bib196","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat. Clin. Pract. Cardiovasc. Med"},{"key":"10.1016\/j.phrs.2023.106843_bib197","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2023.106843_bib198","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/1744-9987.13780","article-title":"G.f.t.G.A.W.G. Scientific Board of, The German Lipoprotein Apheresis Registry-Summary of the ninth annual report","volume":"26","author":"Schettler","year":"2022","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.phrs.2023.106843_bib199","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2023.106843_bib200","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J. Lipid Res"},{"key":"10.1016\/j.phrs.2023.106843_bib201","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu. Rev. Pharmacol. Toxicol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823001998?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823001998?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:22:03Z","timestamp":1777605723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823001998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":201,"alternative-id":["S1043661823001998"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106843","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106843"}}